Jaguar Health (NASDAQ:JAGX) Research Coverage Started at

Investment analysts at began coverage on shares of Jaguar Health (NASDAQ:JAGXGet Free Report) in a report issued on Monday. The firm set a “sell” rating on the biotechnology company’s stock.

Jaguar Health Stock Performance

JAGX opened at $0.32 on Monday. The company has a 50-day moving average of $0.32 and a 200-day moving average of $0.50. Jaguar Health has a 1-year low of $0.21 and a 1-year high of $11.99. The company has a debt-to-equity ratio of 2.89, a current ratio of 0.97 and a quick ratio of 0.69.

Jaguar Health (NASDAQ:JAGXGet Free Report) last released its earnings results on Monday, August 14th. The biotechnology company reported ($0.42) EPS for the quarter. Jaguar Health had a negative return on equity of 1,146.88% and a negative net margin of 402.00%. The business had revenue of $2.68 million during the quarter. As a group, analysts forecast that Jaguar Health will post -5.83 EPS for the current year.

Institutional Investors Weigh In On Jaguar Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in JAGX. Citigroup Inc. acquired a new position in Jaguar Health during the first quarter valued at approximately $34,000. Goldman Sachs Group Inc. lifted its position in Jaguar Health by 153.3% during the first quarter. Goldman Sachs Group Inc. now owns 54,770 shares of the biotechnology company’s stock worth $39,000 after purchasing an additional 33,148 shares during the period. Acadian Asset Management LLC bought a new stake in Jaguar Health during the first quarter worth about $43,000. Geode Capital Management LLC bought a new position in shares of Jaguar Health in the second quarter worth about $48,000. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Jaguar Health by 507.3% in the first quarter. Bank of New York Mellon Corp now owns 169,749 shares of the biotechnology company’s stock worth $120,000 after acquiring an additional 141,796 shares during the last quarter. Institutional investors and hedge funds own 12.24% of the company’s stock.

Jaguar Health Company Profile

(Get Free Report)

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

Recommended Stories

Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with's FREE daily email newsletter.